Innovation Theater: Epidermolysis Bullosa in Practice: Addressing Clinical Challenges, Emotional Impact, and Evolving Wound Therapies (non-accredited/non-approved for CECH)

Led by industry specialists in the Epidermolysis Bullosa (EB) field.

Supported by CHIESI USA, Inc.

Learning objectives:
1. Describe the pathophysiology, genetic heterogeneity, and clinical manifestations of Epidermolysis Bullosa (EB), including key subtypes, wound characteristics, and subtype-specific risks of long-term complications.
2. Discuss evidence-based, multidisciplinary approaches to EB management, addressing wound care, systemic and psychosocial burden, and supportive care needs across the disease continuum.
3. Evaluate the impact of EB on patients, families, and caregivers using clinical and patient-reported outcomes, and identify practical strategies to address unmet needs and improve quality of life.
4. Review available and emerging wound management approaches for EB, including topical therapies, with attention to mechanisms of action, approved indications where applicable, limitations of the evidence, and their role within comprehensive care.